Major Advances are Afoot in Management of ATTR Cardiac Amyloidosis | oneAMYLOIDOSISvoice

Major Advances are Afoot in Management of ATTR Cardiac Amyloidosis

Cardiac amyloidosis, traditionally considered a rare and dire disease, is receiving increasing attention as sophisticated diagnostics are identifying more patients and novel therapies are emerging to combat it. Among the latest signs of progress are the encouraging results of the ATTR-ACT study of the drug tafamidis presented as a late-breaking trial at the European Society of Cardiology Congress in late August and simultaneously published online by the New England Journal of Medicine.
Tafamidis was studied for treating one of the two main types of cardiac amyloidosis — transthyretin (ATTR) amyloidosis, which is caused by misfolding of the liver-derived transthyretin protein, leading to amyloid fibril formation and deposition in the myocardium. Although both types cause cardiac amyloidosis, ATTR amyloidosis is a very distinct disease from light chain (AL) amyloidosis, in which plasma cells in the bone marrow produce an amyloidogenic light chain fragment. The pathophysiology, prognosis and treatment of the two types differ considerably.
Major Advances Are Afoot In Management Of ATTR Cardiac Amyloidosis

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.